+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are studying women who carry mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 to better understand their risk of developing cancer. This observational study aims to collect national data from women with these mutations, as current management strategies are not fully established. The study focuses on the Italian population, where an estimated 140,000 to 150,000 women carry these mutations, and many face a high lifetime risk of genetically linked tumors. Participants will be registered on a platform where their clinical data related to BRCA1 or BRCA2 mutations will be collected. The study does not involve treatment but gathers detailed information about mutation distribution, access to genetic evaluation, lifestyle risk factors, preventive strategies, and surgical risk reduction approaches such as salpingo-oophorectomy. Women in the study will provide data that researchers will analyze to understand mutation geography, related cancer types, and screening criteria. Data collection occurs over different time frames, including immediate and six-month intervals. The study continues through long-term observation to monitor outcomes and preventive efforts, with no active intervention applied to participants.

Age: 18Years +FEMALE
40 locations
S

Actively Recruiting

Researchers are studying how infertility affects sexual function in couples undergoing assisted reproduction and comparing them to fertile couples who have had at least one full-term pregnancy without assisted reproductive technology. The study evaluates sexual health using validated questionnaires designed to assess sexual satisfaction, anxiety, depression, and fertility-related problems. Both infertile and fertile couples attending a urology and reproductive technology clinic are included. All participants will complete several questionnaires the Index of Sexual Satisfaction and the Depression Anxiety Stress Scale. Infertile couples will also complete the Fertility Problem Inventory. Male participants will fill out the International Index of Erectile Function, while female participants will complete the Female Sexual Function Index. Data collection occurs at the start of participation without any drug or device interventions. Participants will undergo standard gynecological and andrological consultations as part of routine care. They will complete self-administered questionnaires to assess sexual health, mood, and the impact of infertility. Researchers will measure sexual health outcomes for men, women, and couples using these tools. No treatments are administered, and the study focuses on collecting and analyzing questionnaire data during the study period, which runs until early 2028.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Researchers are investigating advanced breast cancer that is hormone receptor-positive and HER2-negative, focusing on patients receiving first-line treatment with CDK46 inhibitors combined with endocrine therapy. The study is observational and multicenter, aiming to gather real-world evidence from clinical data, medical imaging, and biological samples. The study includes various sub-studies that address different aspects of treatment outcomes and patient responses. The study involves collecting data from five sub-studies real-world clinical data comparing survival outcomes among patients treated with three CDK46 inhibitors safety data on comorbidities, medications, and toxicities medical imaging analyses using CT and PET scans genomic and transcriptomic analyses from tumor samples and evaluation of treatment patterns after progression on first-line therapy. These sub-studies use different methods for data collection, extraction, and analysis to build predictive models to assist treatment decisions. Participants will have their medical records reviewed for clinical outcomes, imaging studies collected and analyzed, and biological samples obtained for molecular testing. Researchers will assess overall survival up to 120 months from treatment start, along with progression-free survival and time to subsequent treatments. The study tracks severe toxicities and gathers detailed comorbidity information to understand treatment safety. Participant involvement is based on data collection rather than active treatment assignment, with the study continuing through various follow-up periods to monitor long-term outcomes.

Age: 18Years +All Genders
24 locations
R

Actively Recruiting

Researchers are evaluating INCB123667 compared to the investigators choice of chemotherapy in women with platinum-resistant ovarian cancer that shows cyclin E1 overexpression. This phase 3, randomized, open-label study aims to assess treatment options for this specific type of ovarian cancer, focusing on progression-free survival and overall survival over up to 2 years. Participants will receive either oral INCB123667 tablets at a dose defined by the study protocol or chemotherapy selected by the investigator according to protocol guidelines. The chemotherapy options are also given at protocol-defined doses. The study compares these two treatment approaches administered in parallel groups. During the trial, participants will be monitored for treatment responses and side effects, with evaluations including tumor measurements according to RECIST criteria and quality of life questionnaires at regular visits for up to 2 years. Safety assessments include tracking adverse events and dose modifications. The study will involve regular visits to assess progression-free survival, overall survival, and other clinical outcomes.

Age: 18Years +FEMALEPhase 3
198 locations
E

Actively Recruiting

Researchers are evaluating the long-term clinical and instrumental response to Cardiac Contractility Modulation CCM therapy in adults with symptomatic heart failure caused by systolic left ventricular dysfunction despite adequate medical treatment. This observational cohort study, both retrospective and prospective, focuses on subjects already receiving CCM as part of their regular care. The study aims to assess clinical response, hospitalizations, quality of life, walking distance, and changes in heart biomarkers over 12 months. Participants carry the OPTIMIZER Smart Mini CCM device, a programmable implantable pulse generator connected to leads in the heart. The study groups are defined by their response to low-dose dobutamine stress echocardiography before implantation, with one group showing a reduction of 15% or more in left ventricular end-systolic volume LVESV and the other less than 15%. The low-dose dobutamine test involves incremental infusions of the drug to assess heart contractile reserve. During the 12-month follow-up, researchers will monitor changes in New York Heart Association NYHA class, hospitalizations, quality of life using the Minnesota Living with Heart Failure Questionnaire, walking test distance, and NT-proBNP biomarker levels. Additional assessments include echocardiographic measures and recording adverse events, cardiac device implants, or surgery. This comprehensive monitoring helps evaluate the clinical and functional effects of CCM therapy over time.

Age: 18Years +All Genders
13 locations
E

Actively Recruiting

The trial investigates whether transcatheter aortic valve implantation TAVI can be safely and effectively performed in hospitals without on-site cardiac surgery for patients with severe symptomatic aortic stenosis. This multicenter, randomized study compares outcomes between centers with and without on-site cardiac surgery to determine if patient safety is maintained when appropriate selection, experienced operators, advanced imaging, and transfer plans are in place. The goal is to improve access to timely treatment while ensuring clinical safety at 1 year. Participants will be randomly assigned to receive TAVI either in a center without on-site cardiac surgery or in a center with on-site cardiac surgery. Both groups undergo the procedure performed by experienced operators following current guidelines and standards. Centers without on-site surgery must have advanced imaging, procedural expertise, and established transfer pathways. Patients will be evaluated beforehand with clinical, echocardiographic, laboratory, coronary, and computed tomography assessments to confirm eligibility and procedural feasibility. During the study, participants will be monitored for clinical outcomes including death from any cause, stroke, and hospitalizations related to the procedure or implanted valve at 1 year. Safety events such as valve-related death and major complications will also be recorded. Clinical events will be reviewed by an independent committee blinded to treatment assignment, and patient safety will be overseen by a data monitoring board. After hospital discharge, participants will have structured follow-up visits to assess health status, adverse events, and hospitalizations, with total participation lasting up to 1 year.

All AgesAll GendersPhase Not Applicable
11 locations